Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (Nasdaq: ENSC) is a clinical-stage pharmaceutical company focused on developing abuse-deterrent opioid therapies and drug-testing technologies, including its TAAP and MPAR platform programs. The company became a public reporting entity through a SPAC merger that closed in 2021, with its 10-Q for the period ended March 31, 2021 filed with the SEC on June 8, 2021 under accession 0001493152-21-013768. Ensysce operates in the healthcare and biotechnology sector, targeting the prescription drug abuse epidemic with proprietary drug formulation science. As of that filing, the company carried the status of a newly public, development-stage biopharmaceutical issuer. Sign up at SpacDesk for full filing history, SPAC transaction details, and ongoing data on ENSC and hundreds of other SPAC-linked companies.